Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prostate-specific membrane antigen + NKG2D ligands CAR T-cells
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
A preclinical **tandem CAR-T-cell therapy concept** designed to target both prostate-specific membrane antigen and NKG2D ligands on tumor cells. The construct combines an anti-prostate-specific membrane antigen single-chain variable fragment with the extracellular domain of the natural NKG2D receptor, enabling recognition of prostate-specific membrane antigen-positive tumor cells as well as tumor cells expressing stress-induced NKG2D ligands. This dual-targeting strategy was developed by Celyad Oncology to address antigen heterogeneity and antigen-negative escape in prostate cancer, including metastatic castration-resistant prostate cancer.
- Other names
- PSMA/NKG2DL tandem CAR T-cellsprostate-specific membrane antigen + NKG2D ligands CAR T-cellsαPSMA/NKG2DL tandem CAR T-cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on prostate-specific membrane antigen + NKG2D ligands CAR T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prostate-specific membrane antigen + NKG2D ligands CAR T-cells.